A full understanding of the methods available for diagnosis, prognosis and stratification are required in order to choose the optimal method depending on the cirumstances. In this video, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Jens Lohr, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the selection and site bias of using bone marrow biopsies for multiple myeloma. Dr Lohr also questions how representative liquid biopsies are.
The biases of using bone marrow biopsies for multiple myeloma
